NCT06042569View on ClinicalTrials.gov

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

March 20, 2030

Study Completion Date

March 20, 2030

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Docetaxel

Given IV

OTHER

Medical Chart Review

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

91010

RECRUITING

City of Hope Medical Center, Duarte

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rising Tide Foundation

OTHER

lead

City of Hope Medical Center

OTHER